Epizyme falls on clinical hold

Epizyme Inc. (NASDAQ:EPZM) fell $2.30 (15%) to $13 in afternoon trading Tuesday after reporting late Monday that FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438). The move shaved $160 million off the company’s market cap...